Podcasts about Checkmate

Making strides against melanoma: how can medical oncologists and interventional oncologists join forces to deliver smarter, patient-centered care? In this episode of BackTable, Dr. Tyler Sandow, hosts Dr. Sunandana Chandra, medical oncologist at Northwestern, and Dr. Riad Salem, interventional oncologist at Northwestern to discuss the evolving management of advanced melanoma. --- This podcast is supported by an educational grant from Replimune. --- SYNPOSIS The doctors open the episode with an overview of melanoma and recent advances in its treatment, highlighting key trials such as DREAMseq and CheckMate 067. The discussion explores the shift from medical oncologist as solo primary providers to a dynamic, multidisciplinary approach to advanced cancer care—emphasizing cutting-edge treatments like immunotherapy and intratumoral oncolytic viruses. Dr. Salem shares practical insights on the procedural techniques of administering intratumoral oncolytics like Replimune, emphasizing the importance of thorough documentation and patient-centered care. The doctors also provide an overview of the ongoing IGNYTE-3 Trial, a Phase 3 study assessing the safety and efficacy of the oncolytic immunotherapy RP1 in combination with nivolumab for the treatment of advanced melanoma. The episode underscores the transformative potential of innovative melanoma treatments and the crucial role of integrated, team-based approaches in improving cancer patient outcomes. --- TIMESTAMPS 00:00 - Introduction03:48 - The Evolution of Melanoma Treatment: From Chemotherapy to Immunotherapy14:05 - The Role of Oncolytic Viruses in Melanoma Treatment20:14 - Interventional Radiology's Role in Cancer Treatment27:00 - Collaborative Approach to Cancer Care32:53 - Hyper Documentation and Communication Efficiency44:47 - Future of Intratumoral Oncolytics48:10 - Multidisciplinary Approach in Advanced Cancer Management51:46 - Conclusion and Final Thoughts --- RESOURCES DREAMseq Trial: Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763 CheckMate 067 trial: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11-22. doi:10.1056/NEJMoa2407417

We warmly welcome you to join Pastor Barry Blankenship in this Sunday morning message!

How God 'flipped the script' on Haman; learning that God will give victory no matter what it takes; a summary of Esther chapters 5-7. To support this ministry financially, visit: https://www.oneplace.com/donate/1213/29

How God 'flipped the script' on Haman; learning that God will give victory no matter what it takes; a summary of Esther chapters 5-7. To support this ministry financially, visit: https://www.oneplace.com/donate/1213/29

In a legal sleight of hand, Republicans want to strip judges of their power to enforce rulings — because holding Trump in contempt might actually work…See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Vintage City Church // Checkmate // Steve AndersonWhen things go wrong in our lives, and unexpected circumstances shake our world, it can be easy to lose hope. But despite what happens, Jesus is always our Savior, Lord, and Hope.

On a stormy night filled with board games and boredom, two siblings answer a knock at the door — only to find two very strange visitors whose motives are anything but clear.FREE Word Search and Crossword puzzles, plus a fun Q&A for you and your kids to see how closely they were paying attenetion to the story! https://weirddarkness.com/mt-checkmateFind more family-friendly frights and creepy games to play on our website at http://MicroTerrors.com!Facebook page: https://www.facebook.com/microterrorsOther stories, novels, and more from author Scott Donnelly: https://amzn.to/3LymHaUOther narrations, podcasts, and audiobooks from voice artist Darren Marlar: https://WeirdDarkness.com= = = = = = = = = = = = = = = = = = = = = = = = = = = = = =Weird Darkness©, 2025Micro Terrors: Scary Stories for Kids™, 2025

Orrin 'Checkmate' Hudson | Mastering Chess, Inspiring Minds, and Changing Lives in Inner Cities. Chess Coach Based in Atlanta GA.

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture As time goes on the people now can see the green new scam was a hoax, Bernie Sanders flies on private jet and Hawaii sues oil industry but spares refinery because they donate to the D party. Inflation is down, the fake news and the Fed were wrong. Trump once again calls on the Fed, he has now boxed them in.Transition to a people's economy is happening. The [DS] has lost all power. Trump has now signaled that he has the power and that the old guard has failed and it in the process of being replaced. What we are witnessing the forced exposure of the corrupt system, the people are seeing it. Now the offensive begins and those who were treasonous to this country will be held accountable. Checkmate. Economy https://twitter.com/mkhammer/status/1921181550239993909 https://twitter.com/libsoftiktok/status/1922302004904280481 https://twitter.com/thehill/status/1922270983534129248 (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");   https://twitter.com/WSJ/status/1922270583930167754 The inflation rate in the United States for April 2021, as measured by the Consumer Price Index (CPI), was 4.2% over the 12 months from April 2020 to April 2021 TRUMP ECONOMIC UPDATE: Inflation Drops to 2.3%, Lowest Since 2021, and US Treasury Records Second Biggest Surplus in History Thanks to Trump's Record Tariff Revenues  https://twitter.com/KobeissiLetter/status/1922268438912798730   https://twitter.com/RapidResponse47/status/1922277662560526415?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1922277662560526415%7Ctwgr%5E9a0647d641b176e03f79d37607411d8da3baf9a9%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fwww.thegatewaypundit.com%2F2025%2F05%2Ftrump-economy-update-inflation-drops-2-3-lowest%2F   Source: thegatewaypundit.com https://twitter.com/Peoples_Pundit/status/1922021412983730442 https://twitter.com/charliekirk11/status/1922286454119829804 https://twitter.com/TrumpWarRoom/status/1908318952838594601 @Taylor47 political class didn't do anything about it—they allowed it to happen!" @USTradeRep"The goal very clearly was to remove U.S. tariffs and trade barriers to make it easier for people to outsource to China." TAKE A LISTEN Trump Just Got Britain To Hit China, UK Politicians Say  British politicians are expressing alarm that the new U.S.–UK trade deal gives President Donald Trump the power to block Chinese investments in critical British infrastructure. The deal announced last week requires the UK to “promptly meet U.S. requirements” to shield supply chains and “relevant production facilities” from foreign investment. If the European country does not meet these requirements, the U.S. can reimpose tariffs, effectively using trade pressure to dictate which countries can invest in the UK's core infrastructure. That clause triggered immediate backlash from British lawmakers and media, who say the U.S. now has a de facto “veto” over foreign investment — specifically Chinese money flowing into the UK's steel and aluminum sectors.   “Washington wants the UK and others to peel away from Chinese trade and investment, especially in sensitive areas like steel,” said Allie Renison, a former trade official, speaking to the FT. Source: dailycaller.com

We are back with The Ledgermain parts 3 and 4. Which is also the conclusion to the Mystery of The Atom... We're looking at issues 61 and 62 of Suicide Squad... Batman, Superman, and Aquaman find out the truth about the death of Ray Palmer... and as the team's name implies... someone dies..... Feel free to e-mail us at taskforcex@headspeaks.com with your thoughts. Visit us on the web at http://taskforcex.headspeaks.com And let us know what you think.

Do product/CRO people REALLY know well? There may be some Dunning Kruger happening, and maybe we really don't get why they keep complaining about our initiatives. Spoiler: Many times, they have a VERY legitimate point! Who better than the freaking VP of Nielsen Norman Group "Checkmate" Kate Moran to come dish all the things we're getting wrong about UX, and how to better work together. We got into: - What product teams/CRO can learn from UX, and vice versa- Why product teams really need to focus on longer term relationships with the customer (and not chasing short term gains)- Amazing (and not so amazing) use cases for AI in UX Timestamps:00:00 Episode Start1:52 How Does UX View Experimentation / CRO?6:51 What Are The Biggest Problems UX Faces As An Industry?13:03 What Can CROs/Product Learn from UX (And Vice Versa)17:22 UX/Product Share This In Common: No One Knows What The Fuck We Do20:55 AI in UX - DON'T (!!!) Blindly Trust It26:56 What Is “Google Gullibility”? 30:51 Context Matters in UX38:05 Shiva Is Kinda Agegist (My Bad lol)Go follow Kate on LinkedIn: https://www.linkedin.com/in/kate-m-moran/ And check out Nielsen Norman's new live online courses!https://www.nngroup.com/training/live-courses/ Subscribe to our newsletter for more memes, clips, and awesome content! https://fromatob.beehiiv.com/If you have listener questions, submit them at https://tinyurl.com/askfromatob for a chance to be featured too!

Beypore Sultan, The Dark Majesty inside me; Tread into the path of him, The Mystic Vlogger. Once you are in, you cannot step back. He will enchant you with his conspiracy theories... Chill you to the bone with his horror stories... Haunt you through the night... Making you wonder about what is real or unreal and intrigue you in the world of the "Illuminati". Unleashing the power of truth to unhide the hidden. It may be worse, not worse than any evil; fears nothing, sees everything. Hunger for more! The mystery travels to the unseen world; retrieving the dark truth hidden within destruction. Wait! That's not all! He will use his magical spell to pull you closer to his kingdom. You cannot resist the temptation.  So, are you game?This Video Link: https://youtu.be/qx6VidWUElAFacebook: https://www.facebook.com/beyporesultanonlineYoutube: https://youtu.be/amnEIluEkzYInstagram: https://www.instagram.com/beyporesultanonlineClubhouse: https://www.clubhouse.com/beyporesultan

Shawna Boren and Dan Kent break down this week's message by Greg Boyd titled: "Checkmate." Grab your beverages and pull up an internet portal to join these two Easter wonks as they breakdown this year's Woodland Hills Easter message.

In this Easter Sunday message, Greg shared with us how on the cross, God lured the rulers of this age into thinking that God could be defeated. However, what looked like defeat was ultimately the path to divine victory. Therefore, we can declare that what looks like Good Friday death is actually a precursor to resurrection victory.

In this Easter Sunday message, Greg shared with us how on the cross, God lured the rulers of this age into thinking that God could be defeated. However, what looked like defeat was ultimately the path to divine victory. Therefore, we can declare that what looks like Good Friday death is actually a precursor to resurrection victory.

Senior Pastor Rufus Smith teaches us this Easter that the uncomfortable truth of life on earth is my believe about demonology, angelology, and Christology matters!Stay connected with Hope Church Memphis:Website • HopeChurchMemphis.comInstagram • @Hope4MemphisTikTok • @Hope4MemphisFacebook • @Hope4MemphisPrayer • HopeChurchMemphis.com/PrayerGiving • HopeChurchMemphis.com/Give

In this Easter Sunday message, Greg shared with us how on the cross, God lured the rulers of this age into thinking that God could be defeated. However, what looked like defeat was ultimately the path to divine victory. Therefore, we can declare that what looks like Good Friday death is actually a precursor to resurrection victory.

Ordained minister, Dr. Dennis Hall, uses the famous painting known as “Checkmate” to demonstrate how life is like a game of chess with Satan as our opponent. He points out how Jesus the King always has one more move to defeat Satan. When it comes to the crucifixion of Jesus, His resurrection was a move unanticipated by his enemies and skeptics. Dr. Hall reviews many of the theories to explain the empty tomb. A discussion of why Pilate, a Roman provincial official had Jesus executed is undertaken. Dr. Hall points out that the ascension of Jesus Christ is another unexpected move that affirmed his divinity. The podcast concludes as Dr. Hall points out that even in the deepest darkest and most depressing times Jesus the King always has one more move. Can also be viewed on YouTube at: https://youtu.be/ZFHgAbKKf9M

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureDoug Burgum halted offshore wind project near NY, Gov Hochul tries to fight back. Foreign investors are dumping stocks.IMF issues warning, Trump is destroying their system. Trump is getting ready to drill baby drill. The Art of the Deal is in action. The [DS] has lost the narrative on MS-13 who was deported. The question is why are the Ds and the fake news concerned about this individual, does he know where the bodies are buried? Scavino sends a message puts up a picture of the President of El Salvador playing chess. What is the objective, in the end it will be checkmate king.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Trump Admin Orders Halt To Offshore Wind Project Near New York Secretary of the Interior Doug Burgum said on April 16 that he had ordered a halt to the construction of a major wind project off the coast of New York “until further review.” Burgum, posting to the social platform X on Wednesday, said he had consulted with Commerce Secretary Howard Lutnick to direct the Bureau of Ocean Energy Management to “halt all construction activities” on Equinor's Empire Wind project. The Biden administration approved the project in 2023, with construction beginning last year. The interior secretary accused the former administration of “rush[ing] through its approval without sufficient analysis.” He did not provide further details on potential faults identified. “On day one, [President Donald Trump] called for comprehensive reviews of federal wind projects and wind leasing, and at Interior, we are doing our part to make sure these instructions are followed,” Burgum wrote in a follow-up post.   In response to the pause, New York Gov. Kathy Hochul said the project had already generated roughly 1,000 “good-paying union jobs” and is contributing to the state's economy. “This fully federally permitted project has already put shovels in the ground before the President's executive orders—it's exactly the type of bipartisan energy solution we should be working on,” Hochul wrote in a statement. “As Governor, I will not allow this federal overreach to stand. I will fight this every step of the way to protect union jobs, affordable energy, and New York's economic future.” According to the University of Maryland Center for Environmental Science, offshore wind farms “can be damaging to fish and other marine species” due to the noise and vibration from both the construction and operation of the wind turbines. Disturbing the sea floor during construction can also “affect plankton in the water column.” Source: zerohedge.com   https://twitter.com/KobeissiLetter/status/1912952517346070939  According to Apollo, foreigners own a massive $18.5 trillion of US stocks, or 20% of the total US equity market. Moreover, foreign holdings of US Treasuries are at $7.2 trillion, or 30% of the total. Investors from abroad also hold 30% of the total corporate credit market, for a total of $4.6 trillion. Foreign investors want out amid the volatility. IMF issues global economy warning The global economy is expected to grow more slowly this year and face higher inflation, the International Monetary Fund (IMF) has said, citing global trade disruptions and rising “protectionism.” Sweeping tariffs imposed by US President Donald Trump, which he says are focused on prioritizing domestic manufacturing and renegotiating trade deals in favor of the US, have caused a sharp rift with trade partners, including the European Union and China.

A quick video clip from THURSDAY FIRE #229 written by BUILD Founder Ben Rogers on February 1st, 2024. Media produced by Dream Free Media, Inc. To learn more about BUILD, please visit www.buildthearmy.com or email brogers@buildthearmy.com. Our mission is to build an army of Disciplined Leaders. Thanks for helping us build the army.

In one bold move, Queen Esther turns the tables, exposes evil, and saves her people. What seemed like a checkmate for the enemy becomes a divine victory for God's people. This week, we dive into Esther Chapter 7 in our study entitled “The Queen's Gambit: Checkmate” and discover how God works behind the scenes and how wisdom, timing, and courage can change everything. God always has the final move. Checkmate! Watch this message on the Authentic Life Fellowship Facebook or YouTube channel. If you "like" our page, you will receive a notification when we go live each Sunday at 9 and 10 a.m. CDT.   Pastor Jimmy's teaching notes are available upon request. Please email him at authenticlifefellowship@gmail.com.

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureCEO Jamie Dimon is calling it, recession is coming. We are already in a recession, Trump will pull us out of it. Ds trying to stop Trump's tariffs. Countries ready to negotiate, Trump pauses tariffs for those countries. China and the EU fight back with reciprocal tariffs, this will not end well for them. Trump main target is the Fed. The [DS] is still trying to use judges to stop Trump's agenda, in the end this will fail. They are trying to use judges in the correct jurisdiction. Trump has set the timeline for the [DS] treasonous acts. Trump will show how the [DS] committed treasonous against the US. In the end Trump will have the final move, checkmate.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy https://twitter.com/KobeissiLetter/status/1909947842845614115   https://twitter.com/WallStreetMav/status/1909935573772738708 Schumer: We Want to Take Tariff Authority from Trump We Allowed Biden to Have Because Trump's ‘Going So Overboard'  Chuck Schumer (D-NY) r  “Congress has always had the power to deal with tariffs, and we've always had these fights in the past on some of the tariff issues as well. But now that Trump is going so overboard, Congress can, has every legal authority to take those powers back, and that's what we aim to do.”  Source: breitbart.com https://twitter.com/disclosetv/status/1909961646929301808 China is the Auto Capital of the World  China is the world's largest car producer and exporter. A little-known fact is that China first became the world's largest car exporter back in 2023, with low-cost EV companies BYD and Chery in the spotlight. The nation's auto sector has been steadily expanding since then, with Chinese brands reaching an all-time high of 69.4% of domestic passenger vehicle market share in Q1 2025. Overall, China exported 5.86 million vehicles in 2024, a 19.3% annual increase. Mexico, Russia, Brazil, and the UAE were the top buyers. China sold 4.96 million passenger vehicles (19.7% YoY increase), 900,000 commercial vehicles (17.5% YoY increase), and 1.28 million new energy vehicles, as well as 987,000 battery-electric vehicles. Japan is the world's second-largest car exporter, exporting 4.22 million vehicles in 2024. This marked a -4.5% decline from 2023. Toyota remains Japan's leading vehicle, accounting for $312.28 billion in revenue and 830,048 million vehicles. Germany is holding onto third place in auto exports. In 2024, Germany exported 3.4 million passenger cars, marking a 2.5% annual increase. Around 25.9% of all vehicles exported from Germany last year were electric. Volkswagen Group remains Germany's star, generating $354.86 billion in revenue for the year. Source: armstrongeconomics.com Scott Bessent Reminds China They Need Access To US Market Far More Than America Needs Access To Their Economy Treasury Secretary Scott Bessent warned that China's decision to retaliate against President Donald Trump's tariffs will ultimately backfire. China announced it is raising tariffs on American goods from 34% to 84% in response to Trump hiking tariffs on Chinese goods from 54% to 104%,   Bessent  thats because China exports far more to the U.S. than it imports, it has more to lose in a trade war. China exported $438.9 billion worth of goods to the United States in 2024 while the U.S. exported $143.5 billion to China, according to the U.S. Trade Representative. Consumer spending in America makes up nearly 70% of its Gross Domestic Product (GDP), according to J.P. Morgan Asset Management.

China has been taking advantage of America for years and Donald Trump has finally showed them who is in charge! Tariffs are being paused for dozens of nations but not for China, their tariffs have just been raised. Who will blink first? Guest: Tim Doesher - Executive Director, Committee to Unleash Prosperity Sponsor: My Pillow Www.MyPillow.com/johnSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After a couple of month delay due to life, Task Force X returns. With The Mystery of The Atom... well, ok, it's actually The Ledgermain parts 1 and 2. Join us as we look at issues 59 and 60 of Suicide Squad... Batman, Superman, and Aquaman find out that The Wall knew about Ray's death before hand and our heroes have some questions. Feel free to e-mail us at taskforcex@headspeaks.com with your thoughts. Visit us on the web at http://taskforcex.headspeaks.com And let us know what you think.

More proof news is here! Following the April 2025 Genetic Evaluations, we learn more about the expansive Colored Breed offering from STgenetics®. In this STtalks we delve into significant advancements in the Jersey, Brown Swiss, Ayrshire, Guernsey and STamina™ breeds, highlighting outstanding bulls like OLEY, GORMAN, JUDSON-P, LASPADA, TESLA, OTHELLO, CHECKMATE, and many more. We also learn about STgenetics® Chromosomal Mating Program®, Ultraplus High Purity™ gender-sorted semen and STgenetics® commitment to technological advancements and breeder success!00:00 Introduction 00:36 Jersey Breed Genetic Evaluations02:36 Highlighting Top Jersey Bulls12:40 Jersey Chromosomal Mating Program®17:02 Brown Swiss Breed Insights17:58 Spotlight on Brown Swiss Bulls24:14 Ayrshire Breed Highlights26:57 STamina™ Lineup and New Releases31:35 Final Thoughts and Conclusion

Relic Radio Thrillers features The Man Called X this week. From November 30, 1947, here's his story, Checkmate In Tahiti. Listen to more from The Man Called X https://traffic.libsyn.com/forcedn/e55e1c7a-e213-4a20-8701-21862bdf1f8a/Thriller887.mp3 Download Thriller887 | Subscribe | Spotify | Support Relic Radio Thrillers Relic Radio Thrillers is made possible by your support. If you'd like to help this show keep coming every week, [...]

Making better information, more consistently accessible is a huge hurdle in the training community. What's even more difficult, is having a space to practice that information, and the associated skillsets. Checkmate Group in Texas has brought a unique spin to the effort, but building their own facility, and granting access to their students to continue their training and growth. Forrest Dohrmann, one of the owners is a dedicated civilian, like many of us, and has invested in his own personal preparedness and the growth of his community. To really get into this and break down why it's important, we sit down and talk about the evolution of the community, the value of an aggressive mindset, and the capacity to be a protector. For as common as being a prepared civilian is, it's still something we don't have nearly enough of, especially when it comes to sharing knowledge and experience. This is a great discussion, and one that I think we'll all relate to.Visit our sponsors!Our Patreon - www.patreon.com/prepared_mindset_podCustom Night Vision - www.customnightvision.comOrion Training Group - www.oriontraininggroup.comOne Hundred Concepts - www.onehundredconcepts.com

Welcome to another episode of the Oncology Brothers! In this episode, Drs. Rahul and Rohit Gosain are joined by their brother, Dr. Timothy Brown from UT Southwestern, to discuss the latest treatment paradigms for upper gastrointestinal (GI) malignancies, specifically focusing on esophageal and gastroesophageal junction adenocarcinoma, as well as gastric cancer. Episode Highlights: •⁠  ⁠Early Disease Management: perioperative FLOT versus concurrent chemoradiation. •⁠  ⁠Adjuvant Nivolumab: Insights from the Checkmate 577 trial and its implications for patients with residual disease post-chemoradiation. •⁠  ⁠Biomarker Testing: The importance of testing for MSI, HER2, Claudin 18.2, and PD-L1 to guide treatment decisions in metastatic settings. •⁠  ⁠Patient-Centered Care: Emphasizing the significance of shared decision-making and multidisciplinary approaches in managing complex cases. Join us as we unpack the nuances of upper GI malignancies and share key takeaways from recent studies and clinical practices.  YouTube: https://youtu.be/UNyi71u2wIw Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms and oncology insights!  

Ian Flood shares how a late-night chess game with his then-flatmate and fellow architect Chris Prosser sparked the idea to design sets inspired by city skylines, with pieces shaped like famous landmarks. He discusses how they founded Skyline Chess and grew it into a thriving business, now featuring 12 cities and a growing portfolio of custom sets for developers, architects and corporate clients.See omnystudio.com/listener for privacy information.

The Avs stay on the winning train as MacKenzie Blackwood gets another shutout win! Martin Necas, LOC, and Jonathan Drouin were the goal scorers tonight. Conor McGahey had the amazing call of how the Avs dismantled old friend Darcy Kuemper and the LA Kings! 

Stephan Livera and James Check discuss the evolving dynamics of the Bitcoin market, emphasizing the shift from traditional market cycles to a more complex interplay of macroeconomic factors and investor behavior. They explore the impact of institutional investors and ETFs on market sentiment, the psychological aspects of trading, and the importance of on-chain metrics in understanding market movements. The discussion highlights the need for investors to adapt their strategies and perspectives in a rapidly changing environment. James emphasizes the importance of understanding market behavior and debunks several false narratives surrounding Bitcoin trading. The discussion also touches on the role of ETFs in the market and how they interact with on-chain data. Ultimately, James encourages listeners to trust their instincts while utilizing available data to make informed decisions in the ever-evolving Bitcoin landscape.Takeaways

Playlist: Roc Marciano & DJ Premier - Armani SectionBlack Milk & Fat Ray - TalcumCurren$y & Harry Fraud - Money MagnetSaba & No ID - a FEW songsReckonize Real & Moka Only - Late EveningMIKE - Then we could be free...Sport Metthews - ConversationsWestside Gunn, featuring Stove God Cooks - ADAM PAGEEs - Clear DesparationQueen Herawin, featuring Breeze Brewin - GluttonyBlack Soprano Family - ImpossibleDaniel Son & Ghost Notes - T.O.Your Old Droog & Madlib - Everything DesignerSmoke DZA - Dirty EurosSy Ari Da Kid, featuring Benny the Butcher - RebellionApollo Brown x CRIMEAPPLE - The ProblemChe Noir x Superior - Destiny RoseMike Shabb - Can't WaitElcamino x 38 Spesh - BabygirlDJ Ritz, featuring Tona & Xentury - AmbitionMazzi & The Soul Purpose - Peyton LockeRedman, featuring Method Man - LalalaDiamond D, featuring Sadat X - Get With ItK-Rec x Checkmate x Moka Only - Love Keep, Pt. 2New Villain x Circa 97 - Lost Smiles

Today's human civilization is still challenged by wars, atrocities, adversity, disturbing events, hardships, losses and so much more. But why? And how is this still possible? Aren't humans good? Aren't humans compassionate and caring? The truth is, not all humans are these very things, instead there is so much darkness and evil still occurring on this planet and people driven by things unexplainable to instigate and cause so much pain and suffering. In this episode you will begin to learn about Demons and demonic influence. The information in this episode stems from the Original Audio, Medical Medium Angels, Demons and Spiritual Tools. There are ways we can protect ourselves from so much we can't see. Get ready to hear the truth and to begin a journey applying powerful tools to protect yourself and the ones you love. In this episode… Discover why you should not fear the word “Demon”. Uncover how Demons might be affecting your life. Learn about “accidents” that happen, relationships that turn sour, dark actions that occur and what these incidents are truly about. Discover if, when bad things happen to someone, whether that person brought it upon themselves or not. Uncover the constant coverups that occur out there to hide the ongoing darkness that keeps truth from showing. Learn about the forces at work and the 16 Spiritual Lights of Free Will. All this and more, tune in and don't miss out on this important episode. You can revisit this episode anytime you need it. For more information visit www.medicalmedium.com

Opening Exercise: The audio will lead you through a series of moves from the beginning of a game. At a certain point, one player will make a mistake and it'll be your job to find the move to punish it. To learn more about Don't Move Until You See It and get the free 5-day Conceptualizing Chess Series, head over to https://dontmoveuntilyousee.it/conceptualization PGN for today's exercise: 1. d4 Nf6 2. c4 e6 3. Nf3 Bb4+ 4. Nc3 b6 5. Bg5 Bb7 6. a3 Bxc3+ 7. bxc3 h6 8. Bh4 d6 9. e3 Nbd7 10. Bd3 g5 11. Bg3 Ne4 12. Qc2 f5 13. O-O Qf6 14. Nd2 Nxd2 15. Qxd2 h5 16. h3 h4 17. Bh2 g4 18. hxg4 h3 19. gxh3 Rxh3 20. f4 Qh4 21. Rf2 Nf6 22. gxf5 Ng4 23. Rff1 { Black to move. Checkmate in two moves. } * And the answer is... 23... Rg3+ (23... Qg3+ 24. Bxg3 Rh1#) 24. Bxg3 Qh1#

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture Trump was able to reduce the egg prices, the fake news argument countered. The [CB] is not building the narrative that Trump will push us into a recession, the Fed is in a holding pattern. The market is coming down and it looks like the globalist are selling off. Trump lets everyone know we are going to go through an economic transition. Elon confirms the target. The [DS] is fighting back, they understand that Trump and the patriots are sitting on a MOAB of information. Panic and pain at the same time. Plus Trump is dismantling the [DS] money machine, and without that they are screwed not just because the can't fund their agenda but because it will point to kickbacks. The [DS] did a test run against X and Rumble. The lesson is not for the treasonous criminals it is for those who are watching. Remember timing is everything, this is not just about producing lists, this is about bring charges against these people. Trump as all the leverage, checkmate.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy https://twitter.com/libsoftiktok/status/1899343346784465393  https://twitter.com/DC_Draino/status/1899210409615216794   to build out AI data centers. We just don't have enough.” I can't believe what I've just heard... WOW! https://twitter.com/BitcoinMagazine/status/1897720645984960893 https://twitter.com/BitcoinMagazine/status/1899109965173776753   https://twitter.com/BitcoinMagazine/status/1899417144057606384 NY Fed: Worry over outlook increases amid stable inflation expectations   Americans grew more worried about the economic outlook in February even as their expectations of the future path of inflation were little changed, a report on Monday from the Federal Reserve Bank of New York said. According to the bank's latest Survey of Consumer Expectations, inflation a year from now is seen at 3.1%, up a hair from January's 3% reading, while the projected level of inflation three and five years from now was unchanged relative to January at 3%. The Fed wants inflation at 2%. Source: reuters.com How Trump provoked a stockmarket sell-off Will the president win back investors? Does he even want to? THE SELL-OFF shows no sign of stopping. America's S&P 500 index dropped by another 3% on March 10th, leaving the world's most watched stockmarket down by almost 9% since its peak last month. The NASDAQ, dominated by tech firms, has fallen by 13%. It is not quite the bold new era of American growth that President Donald Trump had in mind. Source: theeconomist.com https://twitter.com/KobeissiLetter/status/1899147246429524222   https://twitter.com/BehizyTweets/status/1899252482213040176  the uncertainty is sowing lots of doubt. President Trump, if the tariffs on Mexico and Canada are settled at 25%, then let's just impose them and keep them in place for a while for stability's sake. Yes, some prices will increase, but the intense winds will force companies to scramble back to America to stay competitive. Canada's Next Leftist Prime Minister Vows to Defeat President Trump and Win Trade War  Canadian leftists have selected Mark Carney as their replacement for Justin Trudeau, Carney will be sworn in as Prime Minister shortly and complete the remaining segment of Trudeau's term before new Canadian elections. So Source: theconservativetreehouse.com Ontario premier threatens to ‘shut off electricity completely' for US if trade war escalates  President Donald Trump may have delayed most – though not all ...

We tend to seek a mate first and then ask for God's blessing later. But what would it look like if we reversed that by seeking God and then allowing Him to direct our steps? When we put God first before moving forward in a relationship, He guides and directs us to the blessing of marriage the way He intended it to be.

When we ask God along the way before taking any steps in a relationship, He will guide and direct us to the blessing of marriage the way He intended for it to be. When in a relationship, it's important to talk through all aspects of the future before diving into marriage. To support this ministry financially, visit: https://www.oneplace.com/donate/640/29

396: Checkmate, restorative justice, WWE has joined the education conversation! Ryan gets into some updates from this week, the newly confirmed Secretary of [soon-to-be-gone] Education, a heartwarming gesture from a student, and much more! Patreon: www.patreon.com/classroombrew Instagram: www.instagram.com/classroombrew

Is This Checkmate? TS WrightThe discussion centers on the alignment of prophetic signs, indicating that the world may be on the verge of significant biblical events. She notes the escalating global conflicts and the pivotal role of Israel in prophecy, emphasizing that the chess pieces are indeed being moved into place for what many believe could be the beginning of the tribulation. He elaborates on the potential implications of Pope Francis, whose health issues are raising questions about his role as the final pope in accordance with Saint Malachi's prophecy. They delve into the technological advancements that are paving the way for a one-world system, including the rise of digital currencies and AI, suggesting these elements are crucial to understanding the impending changes in global governance. Throughout their conversation, they stress the necessity for individuals to remain spiritually vigilant and prepared for what lies ahead, aligning their actions with biblical teachings and prophecies.Takeaways: Pastor Bob Thibodeau emphasizes the significance of prophetic signs currently aligning globally, indicating a potential approach to the tribulation period. The discussion centers around Israel's pivotal role in biblical prophecy, particularly the implications of the Abrahamic Accords on future events. Scott Wright articulates that current geopolitical tensions, including the actions of Iran and relations with Saudi Arabia, are critical indicators of prophetic fulfillment. The podcast explores the technological advancements influencing a centralized global governance, connecting these trends to biblical prophecy and the emergence of the Antichrist. Wright asserts that the state of Pope Francis' health, as prophesied by Saint Malachi, could signify approaching end-time events, warranting close observation by believers. Listeners are encouraged to actively prepare spiritually and emotionally for upcoming challenges, emphasizing the necessity of prayer and evangelism in contemporary times. CONTACT INFORMATION:Email:   gccgodcenteredconcept2038@gmail.com Book:  “God Centered Concept Journal: Making God's Word My Ways.”  - on Amazon Podcast:  The God Centered Concept _____________________________________________Check Out These Amazing LinksPastor Bob "HIGHLY" recommends "Captivate.FM" as YOUR podcast host! They have a lot of very helpful features (and more all the time) - and NO CHARGE for the features or upgrades!ModernIQs is a sponsor of the Kingdom Cross Roads Podcast Newsletter: Transform your creative workflow with ModernIQs! Explore AI-powered tools for content creation, from smart question generators to automated blog writers. Streamline and create with ease! Go to ModernIQs.com for more information!Grow your faith and your business with The Faith-Based Business Newsletter! Get practical tips, biblical insights, and strategies for success. Subscribe at

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology. Episode Highlights: •⁠  ⁠TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing. •⁠  ⁠NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab. •⁠  ⁠CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line. •⁠  TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies. Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review! YouTube: https://youtu.be/OzeHhyAdF9Q Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and updates from the Oncology Brothers!

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

The Marceline takeover nears its end as the Oh My Glob crew discuss "Stakes" parts 6 and 7!For Amy's episode predictions, we present... Caroline's Handy Dandy Grading Rubric:  Does the prediction contain the same characters as the actual episode? If I worked at A.T. corp. would I produce this episode idea?  How much creative effort was put forth while coming up w/ this prediction? Do the prediction and the actual ep. follow the same archetype (i.e. love & loss, heroic adventure, self-discovery, etc.)?  Would this story aide in the development of the overall plot and/or character development?  Do the events of the story seem plausible in regard to character traits (i.e. It would not be plausible for Finn to do something evil)?  Does a similar story line occur at some later point in the show? Has a similar story line already occurred in a previously reviewed episode?Rate us on Apple Podcasts! itunes.apple.com/us/podcast/oh-my-glob-an-adventure-time-podcast/id1434343477?mt=2Facebook: facebook.com/ohmyglobpodcastContact us: ohmyglobpodcast@gmail.comAnd that Twitter thing: https://twitter.com/ohmyglobpodcastAmy: https://twitter.com/moxiespeaksTrivia Theme by Adrian C.

Beverly Hills Precious Metals Exchange - Buy Gold & Silver https://themelkshow.com/gold/ Speak with Gold Expert Andrew Sorchini…Tell Him Mel K Sent You!   Learn more about & follow James Howard Kunstler: https://kunstler.com https://x.com/Jhkunstler https://jameshowardkunstler.substack.com/ https://kunstler.com/writings/clusterfuck-nation/   Order Mel's New Book: Americans Anonymous: Restoring Power to the People One Citizen at a Time https://themelkshow.com/book   Dr. Zelenko Immunity Protocols https://zstacklife.com/MelK   We The People must stand strong, stay united, resolute, calm, and focus on the mission.   We at www.themelkshow.com want to thank all our amazing patriot pals for joining us on this journey, for your support of our work, and for your faith in this biblical transition to greatness. We love what we do and are working hard to keep on top of everything to help this transition along peacefully and with love. Please help us amplify our message: Like, Comment & Share!   The Show's Partners Page: https://themelkshow.com/partners/ Consider Making A Donation: https://themelkshow.com/donate/   Another way to get involved and find ways to become active in the community is to come meet Mel and many amazing truth warriors at our upcoming live in-person speaking events. Together we are unstoppable. We look forward to seeing you. God Wins! https://themelkshow.com/events/ Remember to mention Mel K for great discounts on all these fun and informative events. See you there! Our Website www.TheMelKShow.com Support Patriots With MyPillow Go to https://www.mypillow.com/melk Use offer code “MelK” to support both MyPillow and The Mel K Show   Mel K Superfoods Supercharge your wellness with Mel K Superfoods Use Code: MELKWELLNESS and Save Over $100 off retail today! https://themelkshow.com/partners/   Healthy Hydration: https://themelkshow.com/partners/   Patriot Mobile Support your values, your freedom and the Mel K Show. Switch to Patriot Mobile for Free. Use free activation code MELK https://themelkshow.com/partners/   HempWorx The #1 selling CBD brand. Offering cutting edge products that run the gamut from CBD oils and other hemp products to essential oils in our Mantra Brand, MDC Daily Sprays which are Vitamin and Herb combination sprays/ https://themelkshow.com/partners/   Dr. Zelenko Immunity Protocols https://zstacklife.com/MelK   The Wellness Company - Emergency Medical Kits: https://themelkshow.com/partners/   Dr. Jason Dean and BraveTV bring you the most innovative and cutting edge science in Nutrition with Nano-Particle Detoxification, The Full Moon Parasite Protocol and Clot Shot Defense. https://themelkshow.com/partners/   Dr. Stella Immanuel, MD. Consult with a renowned healthcare provider! Offering Telehealth Services & Supplements. Use offer code ‘MelK' for 5% Off https://themelkshow.com/partners/   Rumble (Video) - The Mel K Show: https://rumble.com/c/TheMelKShow Twitter: https://twitter.com/MelKShow Twitter (Original): https://twitter.com/originalmelk TRUTH Social: https://truthsocial.com/@themelkshow Instagram: https://www.instagram.com/themelkshow/ CloutHub: https://app.clouthub.com/#/users/u/TheMelKShow Mel K Show Video Platform (Subscription): https://www.themelkshow.tv Bitchute: https://www.bitchute.com/channel/Iw2kiviwZpwx/ Podbean: https://themelkshow.podbean.com/ Gab: https://gab.com/MelKShow GETTR: https://www.gettr.com/user/themelkshow Locals.com: https://melk.locals.com/ Banned Video: https://banned.video/channel/the-mel-k-show Brighteon: https://www.brighteon.com/channels/themelkshow

Kelsey O'Malley interviews Tim Sheets. Apostle Tim discusses the current reset in our nation and the church, the prevailing church, governmental angels, and more! You can connect with Apostle Tim at www.oasiswired.org and www.timsheets.org. Thank you for making the always-free Elijah List Ministries possible! Click here to learn how to partner with us: https://ElijahStreams.com/Donate Prefer to donate by mail? Make your check or money order (US Dollars) payable to: “ElijahStreams” and mail it to: ElijahStreams, 525 2nd Ave SW, Suite 629, Albany, OR 97321 USA

As the ineffective, bloated bureaucrats take out their checkers, President Trump and DOGE are playing 9-dimensional chess, scoring checkmates and landing blows to the establishment. CNN tries to sound the alarm but gets blistered by Mr. Wonderful. DOGE announces it's already cut $100B from the ridiculous federal budget as more Americans begin to see politicians howling about fraud being exposed as GUILTY and COMPLICIT. Trump's deputy chief of staff Stephen Miller drops a 100% guarantee that DOGE is protecting Americans' information, not stealing it.

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

The Break Room (WEDNESDAY 2/12/25) 7am Hour 1) Duffy would like to request a government issued "Get Out Of Conversation Free" card just in case he's ever in this situation in the future 2) A neighbor dispute over some slippery steps leads to one man's arrest 3) We are ALL Slick Rick

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125737 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS Drs. Burgoyne and Mizrahi provide a primer on immunotherapy and explain how they communicate the principles of this treatment to their patients. Dr. Du discusses the Imbrave clinical trial and how recent studies have shown improved overall survival when immunotherapeutic agents are used, especially when multiple agents targeting various pathways are employed. When choosing between different regimens, the doctors consider factors such as the patient's underlying liver function, symptom burden, and prior treatments. Importantly, the doctors also discuss contraindications to immunotherapy, including a history of organ transplant, autoimmune disease, and poor performance status—all of which put patients at high risk for deterioration with this treatment. The treatment of patients with poor liver function remains controversial, as underlying cirrhosis may prevent the recovery of liver function. Dr. Berman outlines recent clinical trials studying the effects of transarterial chemoembolization (TACE) combined with immunotherapy. Finally, the doctors discuss the future of HCC treatment and the benefits of continued innovation in both interventional and medical oncology. --- TIMESTAMPS 00:00 - Introduction to Immunotherapy 04:32 - Notable Clinical Trials 13:39 - HCC Etiology and Immunotherapy Outcomes 18:43 - Contraindications for Immunotherapy 23:05 - Adverse Effects from Treatment 25:14 - Combination Therapy 36:22 - Considerations for Immunotherapy Dosing 40:26 - The Future of HCC Treatment --- RESOURCES Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, IMbrave150 Trial (Finn et al, 2020): https://pubmed.ncbi.nlm.nih.gov/32402160/ Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, HIMALAYA Trial (Abou-Alfa et al, 2022): https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial (Yau, 2022): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/abstract Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW (Galle, 2024): https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4008 Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (Llovet, 2022): https://pubmed.ncbi.nlm.nih.gov/35119481/ Find this episode on BackTable.com for more resources.

CHECK MATE as they say! It's time for one final mystery to take place at Hawthorne House and your resident hosts and puzzle-makers Meggie and Laure are here to dissect all the clues and plot to their hearts content.  It's been almost a year since Avery came to Hawthorne House and inherited billions of dollars, its also been almost a year of her dating Jameson Hawthorne while still thinking about his brother Grayson (yeesh!). Mystery girl/Toby's real daughter Eve shows up after Toby goes missing and it's up to the gang to put their heads together to bring Toby back.